Our leadership team has experience
throughout the drug development
process, from drug discovery
through to commercialization
Chief Executive Officer
Robert W. Duggan joined the Board of Directors in December 2019 and has been the Executive Chairman of our Board since February 2020. Mr. Duggan has served as our Chief Executive Officer since April 2020.
Since 2015, Mr. Duggan has also been the Founder and CEO of Duggan Investments, a venture capital and equity investment firm. His firm’s investments primarily focus on patient-friendly breakthrough solutions to complex diseases that extend patients’ lives.
From 2008 to 2015, Mr. Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of certain cancers. Mr. Duggan led both the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Johnson & Johnson in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie for approximately $21B remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
From 1990 to 2003, Mr. Duggan was Chairman of the Board of Directors of Computer Motion, Inc., a groundbreaking robotic surgery company that helped change the way in which many surgical procedures are performed around the world with the assistance of its minimally invasive, robotics-based surgical systems. From 1997 to 2003, Mr. Duggan also served as CEO of Computer Motion. In June 2003, Computer Motion merged with Intuitive Surgical, Inc. From the completion of the merger in 2003 until 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical.
Mr. Duggan received a US Congressional Medal of Merit from Congressman Dr. Ron Paul in 1985. In 2000, he was named a Knight of the Legion D’Honor by President Jacques Chirac of France.
Beyond Summit, Mr. Duggan is currently the Chairman of the Board at Pulse Biosciences, Inc., and is also a member of the University of California at Santa Barbara Foundation Board of Trustees. Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences, as well as a Chair in Religious Studies at the University of California at Santa Barbara.
Dr. Maky Zanganeh
Co-Chief Executive Officer & President
Maky Zanganeh, DDS, has served as Summit’s Co-Chief Executive Officer & President since July 2022, having previously served as our Chief Operating Officer since joining Team Summit in November 2020. She is also a member of the Board of Directors
She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device, and technology industries.
Most recently, Dr. Zanganeh is the Founder & CEO of Maky Zanganeh and Associates (“MZA”). Prior to starting and leading MZA in 2015, Dr. Zanganeh held multiple leadership positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her role as Chief Operating Officer, where she oversaw all clinical, research, commercial, and business-related matters. Dr. Zanganeh played a key role both in the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
Previously, she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates, a private investment firm, and Computer Motion, Inc., a pioneer in robotic surgery.
Dr. Zanganeh earned FierceBiotech’s “Top Women in Biotech” award in 2013. She received her DDS from Louis Pasteur University (France) and her MBA from Schiller International University (France).
Beyond Summit, Dr. Zanganeh is currently a board member for Pulse Biosciences, Inc., as well as her role as the Founder & CEO of MZA.
Head of Information Technology
Will Black is our Head of IT responsible for all IT infrastructure, systems, and processes at Summit. He is also responsible for Computer System Validation and works closely with all business departments and Quality Assurance to ensure that Summit’s GxP systems meet FDA and EMA criteria.
Mr. Black was previously at Iovance Biotherapeutics where his most recent project was designing IT systems and infrastructure for the largest US GMP cell and tissue therapy manufacturing facility. Prior to that he spent 8 years at Pharmacyclics leading IT and supporting R&D where he was the principal SME for all IT inspections and audits.
Mr. Black received his BSc from Napier University (UK) and has worked professionally in the UK, the Middle East, and the US for the last 30 years.
Head of Market Access
Rodney Brown is our Head of Market Access. Mr. Brown is responsible for leading the development and execution of strategies to secure and maintain optimal market access for Summit’s medicinal therapies in the US.
Mr. Brown has over 25 years of experience as a leader in the bio pharmaceutical industry, primarily in the infectious disease space, establishing strategic commercial planning for organizations and a framework to enable patients with access to medication. Mr. Brown joined Summit from Gilead Sciences, where he was the Brand Market Access Lead for their HIV portfolio, and has held senior management positions in Sales, Market Access, and Operations at Achaogen, Durata Therapeutics, Takeda Pharmaceuticals, and Baxter Healthcare.
Mr. Brown earned a Master’s degree in Health Care Management from Webster University.
Dr. Betty Chang
Head of Research, Oncology & Inflammation
Betty Y. Chang, PhD, is our Head of Research, leading efforts for discovering new molecules for our growing pipeline.
Prior to Summit, Dr. Chang was Senior Vice President of Translational Research and Early Development, part of the executive team, of Molecular Templates, an immunotoxin company where she was responsible for pharmacology, toxicology, and clinical PK/PD functions. From 2018-2019, she was Chief Operating Officer & Executive Vice President of Product Development at Angarus Therapeutics, an early-stage start-up. From 2009-2018, she was at Pharmacyclics (acquired by AbbVie in 2015) where she was ultimately the Head & Vice President of Research. In that function, she built and led the strategy and operations of a team responsible for drug discovery, pharmacology, translational medicine, and early development activities for IMBRUVICA® (ibrutinib). Dr. Chang started her career at Cell Genesys, a gene / cell therapy company in 1999, and then was an Associate Director at Rigel and Alder Biopharmaceuticals with increasing responsibilities in research and development.
Dr. Chang has published over 100 research manuscripts, conference abstracts, and patent publications. Dr. Chang received her Ph.D. degree in Biochemistry and Molecular Biology from the University of California, Davis, and completed her postdoctoral fellowship in cancer biology at Stanford School of Medicine.
Dr. Fong Clow
Head of Biometrics
Fong Clow, D.Sc., is our Head of Biostatistics, Data Management, and Statistical Programming. She provides strategic leadership and analysis to the product development cycle.
Dr. Clow brings over 30 years of experience leading extensive teams in biometrics and drug development. She joined us from Pharmacyclics, an AbbVie company, where she was the SVP of Biostatistics, Statistical Programming, and Clinical Data Management. Prior to AbbVie, Dr. Clow held leadership roles at Genentech and several biotech companies. Dr. Clow has had 14 successful NDA / BLA submissions and approvals, including 11 in oncology for IMBRUVICA® (ibrutinib). She has received multiple awards for her accomplishments and contributions, including the 2019 Lagakos Distinguished Alumni Award from Harvard T.H. Chan School of Public Health.
Dr. Clow received her Doctor of Science and Master of Science degrees from Harvard School of Public Health.
Chief Financial Officer
Mr. Dhingra brings over 25 years of finance and accounting experience in Diagnostics, Life Sciences Tools and Electronics Tools industries. Most recently, Mr. Dhingra was CFO at CareDx – company focused on transplant patient journey – where he was responsible for Finance, IT and Market Access functions. Prior to that Mr. Dhingra spent 18 years at Agilent Technologies in various finance and business management roles. His final role at Agilent was Vice President of Investor Relations; prior to that Group CFO for Agilent’s Life Sciences and Applied Markets business.
Mr. Dhingra has demonstrated a track record of success scaling businesses by executing and influencing growth-oriented business strategies, expanding margins and deploying M&A policies. He has extensive experience managing global teams of finance and accounting professionals. Mr. Dhingra is a Chartered Accountant from The Institute of Chartered Accountants of India. Beyond Summit, Mr. Dhingra is Advisory Board Member at InstaMortgage
Dr. Andy Dwyer
Head of CMC & Supply Chain
After completing his Ph.D in Synthetic Organic Chemistry at Southampton University, UK, Dr. Dwyer joined GSK in 2004, in Worthing, UK as a Senior Scientist, technically supporting oral solid dose antibiotic production. Subsequent moves saw Dr. Dwyer work as a Development Team Leader in “Biotechnology Development” and an Innovation Leader within “Chemistry Development”. In 2011 Dr. Dwyer took up the position of R&D API Pilot Plant Director in GSK Jurong, Singapore. Dr. Dwyer returned to the UK in 2014 to pursue a global role accountable for GSK R&D Clinical Packaging Operations (with incremental experiences in supply chain management, global logistics and IRT). In June 2019 Dr. Dwyer transitioned into the role of R&D Drug Product Pilot Plant & Global Manufacturing Technologies Director in Ware, UK. During this time Dr. Dwyer also sat on various government/industry collaborations including: the “medicines manufacturing innovation centre LT” (MMIC-LT) and the “pharma innovation programme Singapore LT” (PIPS-LT). As of May 2022, Dr. Dwyer joined Summit Therapeutics as Head of CMC & Supply Chain.
Head of Stakeholder Relations & Corporate Strategy
Dave Gancarz, CPA, is our Head of Stakeholder Relations and Corporate Strategy, who provides strategic leadership over our company’s business development, corporate affairs, corporate strategy, and investor relations functions, as well as communications with our various stakeholders. Mr. Gancarz’s previous experience focused on commercial finance, general corporate finance, and public accounting.
Mr. Gancarz joined Summit from Athenahealth, Inc., where he most recently led the commercial finance team, where he oversaw the company’s overall pricing strategy, deal pricing, deal desk, deal administration, and sales operations functions. Prior to that, he held leadership positions in accounting at Athenahealth. Mr. Gancarz began his career at PricewaterhouseCoopers, where he was a Senior Manager in the Boston, MA and Miami, FL offices.
Mr. Gancarz received his MSA and BSBA degrees from Stonehill College and is a Certified Public Accountant in Massachusetts and Florida.
Dr. Urte Gayko
Head of Regulatory Affairs, Quality Assurance, & Safety
Urte Gayko, Ph.D., is our Head of Regulatory Affairs, Quality Assurance, and Safety. She provides strategic and scientific leadership throughout the product development cycle.
Dr. Gayko brings over 20 years of experience leading extensive teams in regulatory affairs, as well as clinical and scientific teams. She joined us from Nektar, where she was the SVP of Drug Development & Regulatory Affairs. Prior to Nektar, Dr. Gayko was the Global Head of Regulatory Affairs and Pharmacovigilance at Pharmacyclics, which was acquired by AbbVie. She was a key member of the Pharmacyclics leadership team which saw 13 approvals for IMBRUVICA® (ibrutinib) over her 8 years there. Prior to joining Pharmacyclics, Dr. Gayko held roles of increasing responsibility at several companies, including Amgen.
Dr. Gayko performed her PhD research in molecular and cellular biology at Harvard University.
Head of Human Resources
Campbell Hair is our Head of Human Resources, and is an HR leader with over 30 years of experience. Most recently, Mr. Hair was the CHRO at Ciklum. Ciklum was an international software development and IT outsourcing company. It was headquartered in London but with software development centres primarily based in Ukraine and other Eastern European countries.
Prior to Ciklum, Mr. Hair was CHRO for Xchanging in the UK, which grew from five hundred employees in the UK to over eight thousand employees in over fifteen countries across South East Asia, North America and Europe. Mr. Hair’s early career began at Ford Motor Company, where he undertook a number of different HR roles including in Manufacturing, Product Development, Sales, and IT working across Europe and the US.
Mr. Hair has a Master of Law (LLM) degree in European Employment Law and a BSc in Business Studies from Leicester University (UK).
Dr. Danelle James
Head of Clinical Development
Danelle James, MD, is our Head of Clinical Development and has the primary responsibility for the clinical development of Summit’s pipeline candidates.
Most recently, Dr. James was the Global Development Lead for IMBRUVICA® (ibrutinib) for Pharmacyclics, an AbbVie Company, after joining Pharmacyclics in 2011. She worked to launch and expand IMBRUVICA® (ibrutinib) globally through scientific oversight and execution of the very broad clinical development program. Prior to Pharmacyclics, Dr. James was a faculty member in the Department of Medicine, Division of Hematology and Oncology, at the University of California San Diego. Her research focus at UCSD for almost ten years, was the study of the Chronic Lymphocytic Leukemia (CLL), non-Hodgkin’s lymphoma, the tumor microenvironment, and the clinical-translational development of agents that can be used to target these interactions. Dr. James started her career in industry approximately 20 years ago at Biogen in Cambridge, Massachusetts, where she worked in the Department of Immunology and Inflammation.
Dr. James has published over 50 peer-reviewed manuscripts. She received her MD from Penn State University College of Medicine and completed her Internal Medicine residency and Hematology / Oncology fellowship at UCSD; she is Board Certified in Internal Medicine and in Hematology. Dr. James obtained a Master of Science degree in Advanced Studies of Clinical Research from UCSD.
Shelley D Spray
Head of Corporate Marketing
Shelley D Spray serves as Head of Corporate Marketing. Ms. Spray has over 25 years in the healthcare industry holding multiple executive roles which include Chief Marketing Officer of Aesthera Corporation (acquired by Solta Medical), where she focused on growth strategies and commercialization of their Isolaz photopneumatic system, and Vice President of Worldwide Marketing at Xlumena Inc. (acquired by Boston Scientific), where she led the development of their launch strategy for its endoscopic ultrasound guided transluminal system. Before this, Ms. Spray was Vice President of Worldwide Marketing at Intuitive Surgical [NASDAQ: ISRG] where she led early commercialization strategies into the US and international markets.
In the late 1990s, Ms. Spray was Vice President and General Manager of the Radiosurgery and StealthNet Divisions of Medtronic, Inc. At Medtronic, she rebuilt infrastructure, redefined divisional focus, and developed B2B and B2C strategies for minimally invasive brain tumor treatments.
Ms. Spray serves on the Board of Directors of Pulse Biosciences. Ms. Spray has been honored with many awards including a prestigious Telly Award and a Business Week Magazine Bronze award for product development and design. Ms. Spray received a BS in Business, Magna Cum Laude, Beta Gamma Sigma, from Arizona State University and graduated from the Competitive Strategic Marketing Program of Columbia University’s Executive School of Business.
Dr. Elaine Stracker
Dr. Juthamas Sukbuntherng
Head of Clinical Pharmacology & DMPK
Juthamas Sukbuntherng, PhD, is our Head of Clinical Pharmacology and DMPK who provides strategic leadership on preclinical and clinical development of our assets and pipelines. She has been involved in early and late development of multiple approved drugs, such as SUTENT® (sunitinib malate), HORIZANT® (gabapentin enacarbil) and IMBRUVICA® (ibrutinib).
Dr. Sukbuntherng has nearly 25 years of experience in drug development from discovery to clinical in biotechnology and pharmaceutical industry. In her latest role at Pharmacyclics, an AbbVie company, she successfully provided clinical pharmacology and DMPK support to the US and global approval of IMBRUVICA® (ibrutinib) for the treatment of several oncology indications. In addition, she provided scientific leadership to cross-functional teams and led several discovery projects.
Dr. Sukbuntherng received her PhD in Pharmacokinetics from the University of Arizona.